Skip to main content
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
- Author(s): Armstrong, William B;
- Taylor, Thomas H;
- Meyskens, Frank L, Jr
- et al.
For improved accessibility of PDF content, download the file to your device.